PrEP and Trial Design — A no brainer for some

Clinical trials for new HIV prevention methods offer participants counseling and access to the existing ways to protect oneself from HIV. It’s called the “standard of prevention” and is a package of prevention methods and services.

Now that oral PrEP is a proven HIV prevention method and WHO-recommended, some trials are adding it to the package. And that makes trials more complex. That’s a good problem to have, says Slim Abdool Karim, the director of the Centre for the AIDS Program of Research in South Africa, also known as CAPRISA. As the co-principal investigator of the landmark CAPRISA 004 tenofovir gel study and the recipient of multiple awards for his research, Karim brings incomparable perspective to this question. In this interview with AVAC’s Jeanne Baron, Karim talks about why designing trials with oral PrEP is a must—scientifically and ethically.

Listen here.

This interview is part of an ongoing series, and look out for our upcoming podcast—Px Pulse, which will feature interviews and discussions that explore vital topics in HIV Prevention research today. Tell us what you think!

Click on the links below to learn more about PrEP and standard of prevention in trials:

New Px Wire: PrEP, money and more

The latest issue of AVAC’s quarterly newsletter, Px Wire, is now available. Check it out for a deep dive into the data that suggest men who have sex with men may be protected by oral PrEP, even if they don’t dose every day—and for the reasons why these data do not apply to women. You’ll also find out why messages about global AIDS are on our mind—and what we’d change about the current global conversation.

Because money matters as much as messages, we’ve provided a centerspread that summarizes current investments, and trends over time, in HIV-prevention research and development. This full-color feature is excerpted from the recently-released report on HIV prevention research and development investment produced by AVAC and partners in the field.

Golden Age or Fools Gold?

Are we in the Golden Age of HIV prevention, as first heralded in Durban, South Africa at the 2016 International AIDS Society conference? Dr. Carl Dieffenbach is the Director of the Division of AIDS at the US National Institutes of Health, (NIH). He oversees one of the largest research budgets in the world for HIV.

In this interview with AVAC’s Jeanne Baron, Dr. Dieffenbach explains the recent progress and upcoming HIV prevention trials, and what it will take to “put out the fire.”

Check out this interview, our first in a series that preview our upcoming podcast — Px Pulse — which will feature interviews and discussions that explore vital topics in HIV Prevention research today.

Listen here.

Want to learn more about the research and trials Dr. Dieffenbach talks about? Follow these links:

On HVTN 702:
On Janssens’s Ad26 Mosaic program:
On HPTN 083 & 084:

Funding Opportunity: RFA-AI-17-028 Next Generation Multipurpose Prevention Technologies (NGM) (R61/R33 – Clinical Trials Optional)

NIAD and NIMH will be accepting applications to support the development of new and innovative multipurpose prevention technologies (MPTs) with the dual purpose of contraception and HIV prevention. Letters of Intent due 19 February 2018.

Informing the Research Enterprise: Webinar with Carl Dieffenbach on future priorities for HIV research networks

UPDATE: The webinar recording is now available: YouTube / Audio / Slides

Join a conversation with US government research leadership about the future of investments in the US National Institutes of Health’s (NIH) HIV clinical trial research networks in the US and internationally. Mark your calendar for Tuesday, September 5 at 2pm ET for a conversation with Dr. Carl Dieffenbach, the Director of the Division of AIDS (DAIDS) at the NIH’s National Institute of Allergy and Infectious Diseases.

Every seven years, the NIH reviews the structure and funding of its HIV clinical research networks. This “network recompetition” process involves decisions that will help determine the focus and priorities of its HIV clinical trial networks through 2027, as well as the number and structures of the various networks that undertake this research. These are critical questions for advocates to weigh in on—whether you are in the US or not.

The webinar will include a brief introductory presentation from Dr. Dieffenbach followed by a Q&A session. NIAID is also currently accepting public comments and questions online, so now is your chance!

Can’t make the webinar but have a question? Please send it on! We will also be scheduling a second webinar at a time more convenient for advocates outside of the US. And, as always, slides and a recording will be posted shortly after the conclusion of the webinar.

Special issue on Sexual and Reproductive Health and Rights Services and HIV: call for papers

You are invited to submit to a special supplement issue on the Integration of Sexual and Reproductive Health and Rights Services (SRHR) and HIV Prevention, Treatment, and Care Services across Sub-Saharan Africa. Selected papers will be published in BMC Infectious Diseases, BMC Public Health and Reproductive Health. Full details, including how to submit manuscripts, can be found here.

PrEP’s Entry into Kenya: Communities hold the key

On July 4, Kenyan civil society, including groups working on the frontlines of HIV prevention and treatment, called a meeting with the leaders and implementers of oral pre-exposure prophylaxis (PrEP) activities in the country. The meeting’s purpose was to have a frank discussion about the role of community support in the national PrEP program, and touch on progress with HIV self-testing implementation. Some of the civil society groups, like ISHTAR-MSM and Bar Hostess Empowerment Support Programme (BHESP), are also involved in implementation—they’ve partnered with Jilinde, a national-scale PrEP rollout project, or LVCT to help identify potential PrEP users, spread messages and deliver services.

Other CSOs in the room, such as Survivors, an NGO of female sex workers in Busia, Western Kenya, and the Kenya Legal & Ethical Issues Network on HIV and AIDS, aren’t delivering services, but, like BHESP and ISHTAR, represent advocates, activists and potential PrEP users. All were united by a common goal of shining a spotlight on community and civil society engagement as a critical link to successful PrEP rollout in the country.

In the months leading up to the May 4 launch of Kenya’s national program, many civil society groups gave inputs to the national PrEP technical working group (TWG), convened by the National AIDS & STI Control Program (NASCOP). This work is ongoing, with civil society represented on the various rollout committees.

But being invited to the table is not the same as setting the table—and at the July 4 meeting, the organizers structured a packed agenda in order to learn about progress and plans, as well as to express their views on priority issues.

Rosemary Mburu, Executive Director of WACI Health, and Nelson Otuoma, Executive Director of the National Empowerment Network of People living with HIV/AIDS in Kenya (NEPHAK), co-facilitated the meeting.

Mburu noted that many issues remain to be worked out if PrEP is to achieve its true potential in the country: communities need to be continuously informed and engaged; sustainable financing that includes domestic resources has to be secured; and county-level plans have to be designed, with appropriate material for use at the community level.

Otuoma, who recently won the inaugural Maisha Conference Award for his work in community advocacy, reminded everyone of PrEP’s massive potential in Kenya, but only “if we can overcome barriers like stigma.”

“Just like ARVs changed the face of HIV from a killer disease to a chronic condition, PrEP can help the country move further and faster along the HIV prevention roadmap,” he said.

Jointly presenting the viewpoint of young women to the convening, 24-year-olds Anastacia Kendi and Grace Kamau, part of the youth-serving group Sauti Skika, welcomed the launch of PrEP, calling it “an empowering tool to women and girls.”

“I hope there will be more investments in ensuring the interventions are made to work for women and girls’ needs alongside the needs of boys and men.”

Three established PrEP implementation projects in Kenya—the Partners Scale Up Project; Introducing PrEP in Combination Prevention (IPCP); and Bridge to Scale (also known as Jilinde, Kiswahili for “protect yourself”)—shared updates and lessons learned.

Speakers from these projects reported excitement about PrEP as a new prevention method in the country. Yet they said that there were obstacles when it comes to actual use. While there are reports of high demand in some communities and programs, there are also places where the number of people signing up to use PrEP is lower than the expected enrollment.

Adherence (taking the pill daily as prescribed) stands out as challenge; and many people who are using PrEP have been “lost to follow-up”, public-health lingo for a participant who starts taking a medication such as PrEP or antiretroviral treatment (for people living with HIV) but along the way stops returning for their monthly refill visits without informing their clinic.

In all updates, community engagement stood out as a critical part of the solution.

Dr Elizabeth Irungu, the director of the Partners Scale Up Project in Thika and Kisumu in central and western Kenya respectively, said the project team is finding broad acceptance for PrEP among heterosexual, HIV-serodiscordant couples.

“We now have something to give the HIV-negative person,” she stated.

Partners dispenses PrEP from Comprehensive Care Centres (CCCs), clinics that are primarily involved with HIV prevention and treatment.

“We think that by adding PrEP for HIV prevention for HIV-negative people, there may be a reduction of the stigma associated with going to CCCs, as both positive and negative people can get services there. However, there is a lot of work to be done to reduce stigma around HIV, and around going to a CCC,” said Irungu.

By June 2017 the project, funded by the Bill & Melinda Gates Foundation, had enrolled 290 couples. They hope to reach 4,800 couples by 2019—200 in each of 24 centers.

Jhpiego’s Jilinde project, also funded by the Gates Foundation, is working among men who have sex with men, sex workers and adolescent girls and young women at high risk for HIV.

Tom Marwa, Senior Technical Advisor at Jhpiego, informed the convening that 2,300 users were enrolled between February and June 2017 through 17 Jilinde PrEP delivery centres in 10 counties of Kenya. The program is on track to reach 20,000 PrEP users by 2020, and its experiences will contribute important lessons to other African countries planning to introduce PrEP, he added.

Introducing PrEP in Combination Prevention (IPCP) consortium, led by LVCT Health, is implementing PrEP among the same populations as Jilinde. The project started before the national launch of PrEP and was designed to test whether PrEP could be delivered to these populations from standard healthcare facilities.

Dr Michael Kiragu, who leads IPCP, said he was heartened to see good support of PrEP during the formative studies phase of the project. Yet out of a target of 2100, only 1626 PrEP users (77 percent of target) were enrolled and retained into the program. He said that this was a sign that there were barriers to PrEP uptake and use.

The project team has learned that an individual’s community has a huge influence on their decision-making, and stigma remains a barrier to PrEP uptake and adherence, he noted.

“PrEP users at IPCP clinics complain about the rattling of pills in the bottle, the color of the pill (blue), and about disapproval from their husbands, boyfriends or parents.” To address some of these challenges clinics have started giving out cotton balls to mute the rattling of pills, holding community dialogues on PrEP with men, and offering couples counseling. In addition, people using PrEP have pointed to support groups as one of the most important resources they depend on to help them maintain good adherence.

Dr Sarah Masyuko, NASCOP’s HIV testing and PrEP Manager, gave a keynote at the convening.

The first phase of communications and advocacy on PrEP had been hugely successful, she noted, with widespread media and social media engagement reaching all corners of the country. On the sustainability question raised by civil society, Dr Masyuko said the Ministry of Health is holding consultations with PEPFAR, The Global Fund, and private companies in Kenya to secure long-term financing for PrEP.

“PrEP rollout is unlike any other,” she noted, citing difficulties with gathering reliable data for an intervention that people can get on and off at will. She said the government is looking into an electronic system with unique identifiers that will help better track users nationwide. She challenged implementing partners to do even more to reach communities with accurate messages on PrEP and HIV self-testing, and that dispel rumours and misconceptions that stand in the way of uptake among eligble persons, defined in the Kenya national guidelines as anyone at substantial ongoing risk of HIV infection.

This background information provided the platform for a robust discussion of what’s working—and what else is needed. Civil society representatives were clear that PrEP messages needed to be highly tailored and that organizations with different positions in the communities needed to have the right infomation to deliver through trusted channels. This could mean fine-tuned messages that go beyond the category of “adolescent girl or young woman,” “sex worker,” or “MSM” to consider other life circumstances—how openly a person is living with his or her identity, their community support, their influencers, et cetera. Some of this work is underway; much more will come from civil society groups leading work on the ground and feeding back on what works and what doesn’t.

From the convening, Peter Mogere, lead pharmacist at the Partners Scale Up Project and 2017 AVAC Fellow, presented a 9-point list of ‘Civil Society Asks’ to the National Technical Working Group (TWG) on PrEP, on 7 July. Along with allocating domestic resources for PrEP, the asks focus on community engagement at the grassroots level; health care provider training; and combating human rights violations, stigma and discrimination.

Mogere said the TWG was highly receptive to the civil society asks; “The TWG Chair said she was looking forward to involving the civil society in reaching out to all communities that would benefit from PrEP. She noted that civil society works on the ground in all regions of the country, including rural areas, and reaching all people at risk of HIV infection is high on the priorities of the national PrEP program.”

As a next step, the advocates are planning to stay connected and to develop and advance priorities that they can pursue through meetings where civil society sets the agenda. The history of the epidemic tells us this is how things change.


AVAC provided technical and financial support for the convening, which was co-hosted by AVAC partners WACI Health and the National Empowerment Network of People living with HIV/AIDS in Kenya (NEPHAK), in collaboration civil society organizations ISHTAR-MSM; Survivors; International Network of religious leaders living with or personally affected by HIV (INERELA+)-Kenya; National Organization of Peer Educators (NOPE); I Choose Life; Health Gap; Bar Hostess and Empowerment Programme (BHESP); Keeping Alive Societies Hope (KASH); Persons Marginalized and Aggrieved (PEMA); Kenya Legal and Ethical Issues Network on HIV and AIDS (KELIN); and Sauti Skika, a project affiliated with NEPHAK.

Announcing the Call for 2018 Advocacy Fellows

UPDATE: We are no longer accepting applications.

AVAC is pleased to announce the call for applications for 2018 Advocacy Fellows. Consider applying to be an Advocacy Fellow and join the 56 Fellows and alumni of the program!

This update provides information on the Advocacy Fellows program, the application process, link to a short informational video and details on an upcoming informational call for interested applicants to be held on Thursday, 10 August 2017.

The submission deadline for Advocacy Fellows applications is Friday, 8 September 2017.

Download application materials at www.avac.org/fellows-application-materials.

About the Program

AVAC’s Advocacy Fellows program was launched in 2009 with the goal to support and expand the capacity of advocates and organizations to monitor, support and help shape biomedical HIV prevention research and implementation worldwide. The program is guided by AVAC’s conviction that effective and sustainable advocacy grows out of work that reflects organizational and individual interests, priorities and partnerships.

The Advocacy Fellows program provides support to emerging and mid-career advocates to design and implement advocacy projects focused on biomedical HIV prevention research and implementation activities in their countries and communities. These projects are designed to address locally identified gaps and priorities. Fellows receive training, full-time financial support and technical assistance to plan and implement a targeted one-year project within host organizations working in HIV/AIDS or related advocacy. Host organizations are critical partners in the program and Fellows’ projects can be an opportunity for an organization to further develop its own work in this field.

The Fellows program focuses on low- and middle-income countries where clinical research on new biomedical HIV prevention options (such as long-acting PrEP, microbicides, multi-purpose prevention technologies, vaccines and related strategies) is planned or ongoing; sites of cure research; or where there is implementation or plans for rollout for proven interventions (such as voluntary medical male circumcision, PrEP, treatment on demand, high impact combination prevention packages) and where there is exploration of strategies for integration of HIV and sexual and reproductive health to reduce risk.

HIV Prevention Research Advocacy Fellows are:

  • Emerging or mid-career community leaders and advocates involved or interested in advocacy around biomedical HIV prevention research and implementation.
  • Individuals with some experience or education in the areas of HIV and AIDS, public health, international development, women’s rights, communications and/or advocacy with key populations, such as adolescent girls and young women, sex workers, gay men, other men who have sex with men and transgender women and people who inject drugs.
  • Based in low- and middle-income countries where biomedical HIV prevention clinical research is planned and/or where implementation of combination prevention packages is planned, ongoing or emerging.
  • Able to collaborate with English-speaking mentors.

Please visit www.avac.org/pxrd to identify countries where research and implementation is ongoing or planned and to learn more about the research. For a list of ongoing trials, visit www.avac.org/summary-tables.

Learn More

Prospective applicants or host organizations who want to learn more about this program or have questions about the application process are encouraged to:

Register for the call here.

If you have any questions about the Fellows program or the application process, please email [email protected].

Applications are due by FRIDAY, 8 SEPTEMBER 2017.

Please share this information with your partners, and we look forward to receiving your application!

Raped at 11, Ntokozo is Finally Able to Tell Her Story, 13 Years Later

This blog post, written by Zizo Zikali, first appeared on What’sUpHIV as part of a series covering the 8th South African AIDS Conference.

gender based violence protestors

Ntokozo Zakwe is a young woman from Hillcrest in KwaZulu Natal who was raped when she was only 11 years old. The man who raped her threatened her and said there would be consequences if she told anyone about it. Now, thirteen years later, she is ready to tell her story.

“The only way I found healing is when I joined DREAMS to help young girls who have been exposed to gender based violence,” says Ntokozo. “Most of them remain silent. The justice system is failing us… how can a person who has caused so much damage in a woman’s life serve only five years?” asks Ntokozo.

DREAMS stands for Determined, Resilient, Empowered, AIDS-free, Mentored and Safe. This initiative runs in South Africa, and also Kenya, Lesotho, Malawi, Mozambique, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe and the aim is to reduce HIV infections amongst adolescent girls and young women. Through DREAMS, Ntokozo receives counseling as a survivor of gender based violence and she also gets to hear about youth friendly health services in her area.

“There are a number of challenges faced by young women,” says Ntokozo. “We have been crying out about the unfriendliness of health care workers in public health facilities. There should more be Thuthuzela Centers, for example, the city of Pietermaritzburg is serviced by one center. I only opened up about the rape case last year after joining DREAMS.”

At the 8th Southern African AIDS conference we heard that unreported cases of gender based violence may hinder the government’s plan to end the HV epidemic by 2030. The conference outlined a range of tools for HIV prevention, but it is important that people know about them. Young women who are raped need to know about PEP, or post-exposure prophylaxis, which is antiretroviral drugs to take after risky sex or rape. At the conference, young women made their voices heard about the challenges they face and the risk of becoming HIV infected.

In South Africa it still difficult to get trustworthy statistics of rape and gender based violence. Many who have survived a rape never report it or they report it only much later like Ntokozo did.

AVAC’s Snapshot from IAS 2017

“To hell with sitting in this meeting. Shut up! Stop talking!” Sibongile Tshabalala, fresh with grief over the recent death of irreplaceable activist Prudence Mabele launched the International AIDS Society meeting in Paris this week with a burning call to action and tribute to both Prudence and activist physician Mark Wainberg. Both, she said, would want far less talk and far more action. She led participants in the Prudence Pledge—which included the essential commitment to be “innovative, unconventional and inconvenient in our approaches to ending the AIDS epidemic.”

Meeting participants stood to take the pledge—and yet the meeting itself continued, one in a field that is now entering its third decade of annual IAS meetings: we feel there’s too much talk, yet we sometimes need to gather in shared grief and to rekindle the fire needed to keep fighting.

And perhaps that’s the task of this, and every, AIDS conference: to hold multiple realities at the same time. There is good news and bad news, often in the same story. There is promise in what’s available today—this is the first meeting where people are reporting on daily oral PrEP delivery, rather than the potential of this new tool. But daily oral PrEP isn’t a magic bullet; and there’s a need to continue finding new tools, too.

An early good news story—first promoted by UNAIDS in its annual progress report last week—that the world is making progress in achieving the 90-90-90 goals, and that these targets (90 percent of people living with HIV knowing their status; 90 percent of those people on ART; and 90 percent of those on ART virologically suppressed) will carry the world towards ending epidemic levels of HIV.

This good news was amplified on Monday with a presentation from the Swaziland Ministry of Health on the 2016 Swaziland HIV Incidence Measurement Survey. Research teams went house to house and, when individuals gave consent, administered HIV tests and collected blood samples that could be tested for the presence of HIV and for viral load. This method gives a more precise, representative picture of the number of people living with HIV in a country than other approaches, such as measuring HIV among pregnant women at antenatal clinics. A survey had been conducted in Swaziland in 2011 using the same methods—providing the first opportunity to compare new HIV diagnoses and levels of virologic suppression in a community over a period where “test and treat” with antiretroviral treatment (ART) was introduced. The good news is: It worked. During a period when ART use nearly doubled, rates of new HIV diagnoses were nearly halved, and HIV virologic suppression doubled. Today, more than 80 percent of Swazi people living with HIV are on ART, and this is very good news indeed.

But is it good enough? Unfortunately, no. As we noted last week, the UNAIDS report—while generally celebratory—contains plenty of reason for concern. There are glaring gaps in primary prevention including PrEP, voluntary medical male circumcision (VMMC), comprehensive harm reduction programs for people who inject drugs, stigma reduction—an issue tackled with eloquence and urgency in the Key Populations Declaration released earlier this week. Even in treatment, the picture isn’t rosy. Overall, the world is not on track to meet Fast Track targets for treatment, either. In 2011, UNAIDS galvanized the world around a goal of universal access to ART; this year’s report shows that just over 50 percent of people living with HIV are on ART. While countries in East and Southern Africa could potentially reach their 90-90-90 targets by 2020, success depends on sufficient resources to sustain the newly achieved speed of treatment scale up. However, West and Central Africa, Caribbean, and Asia Pacific are all not on track to hit the 90-90-90 targets.

Even in Swaziland, there’s a need to look more closely. Young people were less likely to know their status, be on ART or be virologically suppressed both in 2011 and 2016. Swaziland has been rolling out a comprehensive package of interventions for the most vulnerable adolescent girls and young women under its DREAMS program—with testing as a core component. The findings would seem to suggest that there is still ground to cover in meeting the needs of girls and women—something Prudence Mabele never stopped saying.

Monday also provided a glimpse of the future of biomedical prevention trials. Hanneke Schuitemaker from Janssen presented results from the APPROACH trial of a vaccine strategy that utilizes a mosaic immunogen—synthetic viral fragments designed to teach the body to defend itself against diverse viral subtypes. This Phase IIa trial measured the safety and immune responses of various pairings of the vaccine containing the mosaic immunogen (known as Ad26, after the adenovirus vector that carries the immunogen into the body) with other “boosts”—vaccines designed to bump up immune responses. All of the trial arms were safe and immunogenic; a combination of Ad26 plus a protein boost had the highest immunogenicity. These data, plus information from the ongoing TRAVERSE trial, will inform the design of a planned efficacy trial, known as HPX2008/HVTN 705.

By the time HPX2008/HVTN 705 starts, two trials of long-acting cabotegravir (CAB-LA) should be underway. On Tuesday, HPTN 077—a study of CAB-LA in 199 men and women in Brazil, Malawi, South Africa and the US—confirmed the findings of the ÉCLAIR CAB-LA study in men: a bi-monthly set of injections with a 600-mg dose of CAB-LA leads to the blood-drug levels thought to be associated with protection; a three-monthly injection with an 800-mg dose does not. Participants continued to report injection-site reactions as discussed in our blog on long-acting injectables. However, the HPTN 077 findings confirm this strategy is safe and tolerated for men and women. In response to a press conference question on whether there were any sex differences seen in HPTN 077, investigator Raphael Landovitz noted that these studies are trying to better understand any PK differences in women and men. The injections go into a “large muscle belly”, which serves as a reservoir to essentially seed blood plasma over time. What governs the differences in drug levels observed? In ÉCLAIR, body-mass index, or BMI, seemed to be associated. In HTPN 077, researchers noted that the rate at which the drug seeps out of the muscle belly into plasma was 50 percent slower in women than in men (which also made for lower peak concentrations after the same dose). This didn’t seem to be linked to body mass index, per Landovitz. Researchers will learn more about whether this difference has any clinical significance during the Phase III large-scale studies (HPTN 083 and 084) that will look at safety and whether CAB-LA is effective for HIV prevention.

At the AVAC-organized prevention satellite on Sunday, US Global AIDS Ambassador Deborah Birx admonished the audience to work with, and on, the multiple realities of today—delivering what’s available, pursuing new options and seeing today’s daily oral PrEP investments as the foundation for a prevention platform. It’s not a contradiction—it’s a continuum.

We must see the world this way—because it’s the only way towards a conclusive end of the epidemic. As Sibongile Tshabalala said, “AIDS isn’t over!! If the party [for the end of the epidemic] starts now, the end will never come.”